Home Amines 183320-51-6
183320-51-6,MFCD22420811
Catalog No.:AA0027F9

183320-51-6 | Ethanol, 2-[[4-[(3-ethynylphenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]oxy]-, hydrochloride (1:1)

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$177.00   $124.00
- +
5mg
98%
in stock  
$311.00   $218.00
- +
10mg
98%
in stock  
$502.00   $352.00
- +
25mg
98%
in stock  
$1,059.00   $742.00
- +
50mg
98%
in stock  
$1,191.00   $834.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA0027F9
Chemical Name:
Ethanol, 2-[[4-[(3-ethynylphenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]oxy]-, hydrochloride (1:1)
CAS Number:
183320-51-6
Molecular Formula:
C21H22ClN3O4
Molecular Weight:
415.8701
MDL Number:
MFCD22420811
SMILES:
OCCOc1cc2c(ncnc2cc1OCCOC)Nc1cccc(c1)C#C.Cl
Properties
Computed Properties
 
Complexity:
511  
Covalently-Bonded Unit Count:
2  
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
10  

Literature

Title: Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.

Journal: Clinical lung cancer 20110901

Title: Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110715

Title: Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110101

Title: Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

Title: Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100501

Title: Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

Journal: European journal of cancer (Oxford, England : 1990) 20090901

Title: Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.

Journal: Cancer chemotherapy and pharmacology 20080901

Title: The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.

Journal: Cancer chemotherapy and pharmacology 20080801

Title: Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.

Journal: British journal of cancer 20080520

Title: Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.

Journal: Anti-cancer drugs 20080201

Title: The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

Title: Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070301

Title: Effects of smoking on the pharmacokinetics of erlotinib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060401

Title: Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.

Journal: Journal of clinical pharmacology 20060301

Title: Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050105

Title: Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030815

Title: Thappali SR, et al. Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.Sci Pharm. 2012 Jul-Sep;80(3):633-46.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:183320-51-6 Molecular Formula|183320-51-6 MDL|183320-51-6 SMILES|183320-51-6 Ethanol, 2-[[4-[(3-ethynylphenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]oxy]-, hydrochloride (1:1)